ライフサイエンスコーパス: neutropenia

1 (mainly diarrhoea, hypertension, and febrile neutropenia).

2 e the mutation burden in HSPCs in congenital neutropenia.

3 s that readily left the circulation, causing neutropenia.

4 (11%) experienced infection with or without neutropenia.

5 gylated interferon alpha (IFN-alpha)-induced neutropenia.

6 by either intrauterine growth retardation or neutropenia.

7 Five (21%) of 24 had grade 3 febrile neutropenia.

8 serious infections, largely due to prolonged neutropenia.

9 ents in group B died of sepsis after febrile neutropenia.

10 at prevents bacterial infections despite the neutropenia.

11 grade 3 and 4 anemia, thrombocytopenia, and neutropenia.

12 tatin-induced myopathy and docetaxel-induced neutropenia.

13 de the mechanism that links its absence with neutropenia.

14 receiving prophylaxis had longer duration of neutropenia.

15 infection in critically ill patients without neutropenia?

16 3), hemolysis (1), thrombocytopenia (4), and neutropenia (1).

17 d fatigue (16%), thrombocytopenia (16%), and neutropenia (10%).

18 There were 29 episodes of febrile neutropenia (10%).

19 on were hematologic, including anemia (15%), neutropenia (11%), and thrombocytopenia (9%).

20 events included fatigue (13.1%) and febrile neutropenia (11.5%).

21 he most common grade 3-4 adverse events were neutropenia (116 [50%] patients in the lenalidomide grou

22 erolimus group versus the placebo group were neutropenia (117 [25%] vs 35 [15%]), stomatitis (59 [13%

23 reported, irrespective of attribution, were neutropenia (117 [66%] of 177 participant cycles in the

24 ts observed in more than 5% of patients were neutropenia (12 [8%] of 152 vs five [3%] of 154 with pon

25 and octreotide, they included fatigue (27%), neutropenia (12%), and nausea (6%).

26 anemia (14.4% and 16.0%, respectively), and neutropenia (12.8% and 4.2%, respectively).

27 [120 mg/day], septic shock [80 mg/day], and neutropenia [120 mg/day]).

28 adverse events in the idelalisib group were neutropenia (124 [60%] of 207 patients) and febrile neut

29 common grade 3 or worse adverse events were neutropenia (13 [10%]), anaemia (11 [9%]), and pneumonia

30 %] of 78), anaemia (14 [18%] vs nine [12%]), neutropenia (13 [17%] vs four [5%]), and fatigue (six [8

31 d 39%), fatigue (13%, 30%, and 20%), febrile neutropenia (13%, 17%, and 6.1%), and anemia (6.7%, 13%,

32 the most common grade 3-4 adverse event was neutropenia (137 [24%] of 571 patients receiving FOLFOX

33 gue (two [1%] each); for ICC, these included neutropenia (14 [14%] of 102), thrombocytopenia (six [6%

34 adverse events in the ofatumumab group were neutropenia (14 [16%]), pneumonia (seven [8%]), and thro

35 mon of which were lymphopenia (15 [21%]) and neutropenia (14 [19%]).

36 at least possibly related to treatment were neutropenia (14 [41%] patients), infection (2 [6%]), and

37 grade 3-4 adverse events in both groups were neutropenia (154 [54%] in the ibrutinib group vs 145 [51

38 , bone pain (16 [5%] vs 5 [2%]), and febrile neutropenia (16 [5%] vs 9 [3%]).

39 icities (grade >/= 3) among all cohorts were neutropenia (16%), leukopenia (11%), anemia (9%), and di

40 acebo plus cytarabine group included febrile neutropenia (167 [47%] vs 117 [33%]), neutropenia (66 [1

41 otransferase), maculopapular rash (17%), and neutropenia (17%).

42 or higher adverse events in cycles 1-4 were neutropenia (175 [16%]) and fatigue (56 [5%]) of the 107

43 or 4 toxicities were anemia, leukopenia, and neutropenia (19% each); lymphopenia (14%); and thrombocy

44 ted adverse events of grade 3 or higher were neutropenia (190 [56%] of 337 patients in the afatinib g

45 ents evaluated for chemotherapy toxicity was neutropenia (197 [74%] of 266 patients in the twice-dail

46 In LUX-Lung 3, neutropenia (20 [18%] of 111 patients), fatigue (14 [13%

47 e), thrombocytopenia (25 [49%] vs 22 [42%]), neutropenia (20 [39%] vs 18 [35%]), pneumonia (15 [29%]

48 v 50.9%) including a higher rate of febrile neutropenia (21.4% v 12.6%).

49 eutropenia (31 [17%] vs seven [8%]), febrile neutropenia (22 [12%] vs ten [11%]), and pneumonia (22 [

50 ocetaxel, fever (18 [12%] and 19 [15%]), and neutropenia (22 [14%] and ten [8%]).

51 Neutropenia (22%) and thrombocytopenia (22%) were the mo

52 most common grade 3 or 4 adverse events were neutropenia (223 [65%] in the fulvestrant plus palbocicl

53 ost common serious adverse event was febrile neutropenia (23 [15%] patients in the aprepitant group v

54 nia (43 [96%] patients), anaemia (41 [91%]), neutropenia (23 [51%]), diarrhoea (21 [47%]), fatigue (1

55 events possibly attributable to therapy were neutropenia (23 cycles, 10 patients), infection (1 cycle

56 B), hypertension (60 [8%] vs 219 [30%]), and neutropenia (241 [33%] vs 275 [37%]).

57 received gemcitabine and docetaxel), febrile neutropenia (26 [20%] and 15 [12%]), fatigue (eight [6%]

58 in 37 (76%) of 49 patients; most common were neutropenia (26 [53%]), thrombocytopenia (eight [16%]),

59 than 2000/mm (28.6% vs 9.8%; P = 0.001) and neutropenia (26.7% vs 7.9%; P < 0.001) in arm A.

60 he most common grade 3-4 adverse events were neutropenia (268 [89%] patients in MAP vs 268 [90%] in M

61 erious adverse events recorded, were febrile neutropenia (27 [17%] of 155 serious adverse events in p

62 10-day schedules, respectively, were febrile neutropenia (27 [53%] vs 25 [48%]), pneumonia (14 [27%]

63 ade 3/4 events, with thrombocytopenia (32%), neutropenia (27%), anemia (23%), and leukopenia (23%) re

64 Grade 3 or higher adverse events included neutropenia (28%), diarrhea (7%), nausea (7%), fatigue (

65 t common serious adverse events were febrile neutropenia (29 [31%] of 93 patients), pneumonia (26 [28

66 PAG v AG) included muscle spasms (13% v 1%), neutropenia (29% v 18%), and myalgia (5% v 0%).

67 herapy-related grade 3-4 adverse events were neutropenia (30 [27%] of 113 patients), vomiting (22 [19

68 p), thrombocytopenia (35 [19%] vs six [7%]), neutropenia (31 [17%] vs seven [8%]), febrile neutropeni

69 s of relationship to treatment, were febrile neutropenia (31 [61%] of 51 patients on the 5-day schedu

70 ost common grade 3 and 4 adverse events were neutropenia (32 [25%] of 128 patients who received doxor

71 ecan plus fluorouracil and folinic acid were neutropenia (32 [27%]), diarrhoea (15 [13%]), vomiting (

72 rade >/=3) adverse events occurred in 84% of neutropenia (32%), alanine transaminase increase (20%),

73 adverse events were thrombocytopenia (47%), neutropenia (32%), anemia (27%), leukopenia (16%), fatig

74 common grade 3 or higher adverse events were neutropenia (321 [31%]) and fatigue (109 [11%]) in the p

75 diarrhoea (33 [15%] vs 2 [<1%]), and febrile neutropenia (33 [15%] vs 0).

76 n in those in the placebo group and included neutropenia (34 [19%] in the ombrabulin group vs 14 [8%]

77 he most common grade 3-4 adverse events were neutropenia (35 [49%] of 72 patients in the vandetanib g

78 worse adverse events (arms A, B, and C) were neutropenia (36%, 33%, and 39%), fatigue (13%, 30%, and

79 oxorubicin versus doxorubicin alone included neutropenia (37 [58%] vs 23 [35%]), mucositis (34 [53%]

80 verse events were thrombocytopenia (48%) and neutropenia (37%).

81 Grade >/= 3 adverse events included neutropenia (39%), leukopenia (16%), anemia (14%), and d

82 (7%), nausea (7%), fatigue (6%), and febrile neutropenia (4%).

83 ost frequent AEs were pyrexia (58%), febrile neutropenia (40%), and headache (31%).

84 al group vs five [1%] in the control group), neutropenia (41 [10%] vs 125 [31%]), and peripheral neur

85 nd thrombocytopenia (25 [11%]) compared with neutropenia (43 [39%]), and anaemia (20 [18%]), in the t

86 he most common grade 3-4 adverse events were neutropenia (43 [40%]), infection (21 [20%]), anaemia (1

87 nt-emergent grade 3 or 4 adverse events were neutropenia (46 [51%] of 91 patients), thrombocytopenia

88 s 65 [21%] of 308 in the doxorubicin group), neutropenia (47 [15%] vs 92 [30%]), febrile neutropenia

89 enia (124 [60%] of 207 patients) and febrile neutropenia (48 [23%]), whereas in the placebo group the

90 ommon adverse event of grade 3 or higher was neutropenia (48 [56%] patients in the subcutaneous group

91 nt-emergent adverse events were hematologic (neutropenia [49.7%], anemia [33.0%], and thrombocytopeni

92 tients), grade >/= 3 adverse events included neutropenia (53% v 49%), thrombocytopenia (13% v 29%), a

93 ts compared with carboplatin-paclitaxel (eg, neutropenia [54% vs 23%; P < .001] and grade 3/4 nausea/

94 ng the combination and maintenance phase was neutropenia (55 [18%] of 312 patients in the GP2013-CVP

95 , and trastuzumab plus pertuzumab group were neutropenia (55 [25%] of 219 vs one [<1%] of 223 with tr

96 ents up to 60 days after last treatment were neutropenia (56 [24%] of 237 patients in the ofatumumab

97 lenalidomide versus placebo maintenance were neutropenia (56% v 22%) and cutaneous reactions (5% v 1%

98 neutropenia (47 [15%] vs 92 [30%]), febrile neutropenia (57 [18%] vs 34 [11%]), leucopenia (22 [7%]

99 t 1 adverse event, the most common including neutropenia (57.5% vs 53.3%), peripheral neuropathy (23.

100 the placebo plus paclitaxel group, they were neutropenia (59 [23%] of 259 patients), leucopenia (27 [

101 in the idelalisib plus ofatumumab group were neutropenia (59 [34%] patients vs 14 [16%] in the ofatum

102 han 10% of the patients in either group were neutropenia (59.3% in the ribociclib group vs. 0.9% in t

103 , thrombocytopenia (7%), dyspnea (6.2%), and neutropenia (6.2%).

104 requent grade 3 or worse adverse events were neutropenia (64 [33%] in the obinutuzumab plus bendamust

105 The most common grade >/=3 toxicity was neutropenia: 64% in MPR, 29% in CPR, and 25% in Rd patie

106 ounced with MPR-R, especially grades 3 and 4 neutropenia: 64% vs 27%.

107 ebrile neutropenia (167 [47%] vs 117 [33%]), neutropenia (66 [19%] vs 49 [14%]), stomatitis (54 [15%]

108 in the custirsen versus control groups were neutropenia (70 [22%] of 315 vs 61 [20%] of 312), anaemi

109 e most common grade >/=3 toxicities included neutropenia (70%), leukopenia (36%), and lymphopenia (20

110 wever, they had a lower rate of grade 3 or 4 neutropenia (72% vs. 83%).

111 ost common grade 3-4 adverse events included neutropenia (73 [44%] of 167 vs 28 [34%] of 83) without

112 e most commonly reported event (grade 3 or 4 neutropenia: 74 [17%] of 446 patients in the CF group vs

113 s in the olaparib plus paclitaxel group were neutropenia (78 [30%] of 262 patients), leucopenia (42 [

114 Common grade >/=3 adverse events were neutropenia (78%), anemia (28%), and leukopenia (24%).

115 The most common adverse event was neutropenia (80 [26%] of 312 patients in the GP2013-CVP

116 s in the rilotumumab and placebo groups were neutropenia (86 [29%] of 298 patients vs 97 [32%] of 299

117 common grade 3 or 4 adverse events included neutropenia (94 [60%] of 157 patients in the lenalidomid

118 The most common toxicities were neutropenia (96%), leukopenia (84%), thrombocytopenia (8

119 ective of relation to treatment were febrile neutropenia (97 [39%] of 252), anaemia (61 [24%]), throm

120 rring in 5% or more of patients were febrile neutropenia (98 [39%] of 252; five related to treatment)

121 3%]), whereas in the placebo group they were neutropenia (99 [47%] of 209) and thrombocytopenia (27 [

122 aglobulinemia, fluctuating monocytopenia and neutropenia, a poor immune response to vaccine antigens,

123 Eligible subjects were those with neutropenia (absolute neutrophil count <500/muL) and pro

124 was significantly associated with prolonged neutropenia after the fourth ( P < .001) and fifth chemo

125 ed reactions (50%) and a higher incidence of neutropenia, although without an increase in infection r

126 mors protected them from doxorubicin-induced neutropenia and anemia while retaining antitumor efficac

127 to irradiation, CD45-SAP completely avoided neutropenia and anemia, spared bone marrow and thymic ni

128 e (IBMFS) that is primarily characterized by neutropenia and exocrine pancreatic insufficiency.

129 , and four additional DLTs were observed: G4 neutropenia and G4 thrombocytopenia at 400 mg and G4 thr

130 ssociated with HSC transplantation including neutropenia and humoral immunodeficiency.

131 Severe neutropenia and infections were more frequently observed

132 uld be suspected in patients with congenital neutropenia and lymphopenia despite the absence of hypog

133 most frequent all-grade adverse events were neutropenia and nausea.

134 The association of neutropenia and NK cell deficiency, which is unusual amo

135 ress this question, we used a mouse model of neutropenia and studied immune activation after adjuvant

136 Prophylaxis prevented febrile neutropenia and systemic infection.

137 Durations of severe neutropenia and thrombocytopenia were prolonged in the i

138 ) and 2 hematologic adverse effects (grade 4 neutropenia and thrombocytopenia, and grade 3 neutropeni

139 ransplantation period (between recovery from neutropenia and up to 6 months).

140 erstitial pneumonia, anaphylaxis, and severe neutropenia) and four in the cisplatin plus gemcitabine

141 the most common of which were hypertension, neutropenia, and anaemia in both groups, and mild-to-mod

142 re-emptive therapy and other factors such as neutropenia, and graft-versus-host disease.

143 yed intrauterine growth retardation, chronic neutropenia, and NK cell deficiency.

144 (and postnatal) growth retardation, chronic neutropenia, and NK cell deficiency.

145 rs plus gastrointestinal disturbance, severe neutropenia, and prior beta-lactam antibiotic use.

146 injury, decreased lymphocyte count, fatigue, neutropenia, and sepsis, and thrombocytopenia.

147 %) patients experienced anaemia, eight (67%) neutropenia, and ten (83%) thrombocytopenia.

148 emotherapy regimen and included lymphopenia, neutropenia, and thrombocytopenia (21 [100%] patients fo

149 New or worsening grade 3 or 4 neutropenia, anemia, and thrombocytopenia occurred in 24

150 The causes of this, and of its precursor neutropenia, are largely unknown, although genetic facto

151 r, liposarcoma, and teratoma with reversible neutropenia as the main toxic effect.

152 hree (11%) of 28 patients, including grade 4 neutropenia at 1.8 mg/kg brentuximab vedotin plus 80 mg/

153 eutropenia and thrombocytopenia, and grade 3 neutropenia, both requiring therapy discontinuation).

154 lp to explain the rather discrepant facts of neutropenia but preserved antibacterial immune defenses

155 ervention in critically ill patients without neutropenia, but the quality of the evidence is low.

156 ure-adjusted incidence rates of grade 3 or 4 neutropenia, candida infections, and Crohn's disease wer

157 malaria severity, and hydroxyurea-associated neutropenia could worsen infections.

158 Febrile neutropenia, diarrhea, and hematuria were more frequent

159 owed that FCR had a higher rate of prolonged neutropenia during the first year after treatment (16.6%

160 events being aminotransferase increases and neutropenia, each of which happened in 3 patients.

161 dverse events in the temsirolimus group were neutropenia (eight [44%] of 18 patients), anaemia (six [

162 common grade 3 or worse adverse events were neutropenia (eight [62%] patients), lymphopenia (seven [

163 se characterized by bone marrow failure with neutropenia, exocrine pancreatic dysfunction and skeleta

164 Outcome was neutropenia, fever, or infection-related hospitalization

165 rse events were pyrexia (six [12%]), febrile neutropenia (five [10%]), lower respiratory tract infect

166 chemotherapy were leucopenia (17 [39%]) and neutropenia (five [11%]), and during chemoradiotherapy w

167 grade 3-4 haematological adverse events were neutropenia (five [28%] of 18 patients), lymphopenia (fi

168 onia (five [5%] and five [11%]), and febrile neutropenia (five [5%] and six [13%]).

169 7%] each), pneumonia (six [6%]), and febrile neutropenia (five [5%]).

170 ) for patients with mantle cell lymphoma and neutropenia (five [63%] of eight) and rash (four [50%] o

171 G) for the empirical management of fever and neutropenia (FN) in children with cancer and hematopoiet

172 resenting with symptoms such as fever during neutropenia (FN).

173 patient) serious adverse events were febrile neutropenia (four [1%] vs one [<1%]) and neutropenia (on

174 even [44%] of 16), hypokalaemia (six [38%]), neutropenia (four [25%]), thrombocytopenia (four [25%]),

175 compared with pneumonia (four [4%]), febrile neutropenia (four [4%]), anaemia (three [3%]), and neutr

176 rug-related grade 3 or 4 adverse events were neutropenia (four [5%] patients) and increased lipase co

177 most common being immune related, nonfebrile neutropenia, gastrointestinal events, and fatigue.

178 The most frequent severe adverse events were neutropenia (grade 3 29 [26%], grade 4 13 [12%] in the T

179 nt adverse event in each treatment group was neutropenia (grade 3, 15 [21%] of 70 patients in the CT-

180 6%]; grade 4, 98 [20%] vs 77 [15%]), febrile neutropenia (grade 3, 52 [10%] vs 31 [6%]; grade 4, four

181 axel and prednisone alone group (n=499) were neutropenia (grade 3, 63 [13%] vs 28 [6%]; grade 4, 98 [

182 ects were primarily hematologic and included neutropenia (grade 3, n = 20 [33%]; grade 4, n = 2 [3%])

183 sh (grade 3, equally common in both groups), neutropenia (grade 4, more common in the co-trimoxazole

184 de was well tolerated; with the exception of neutropenia, grade 3-4 toxicities were uncommon.

185 %] of 108; group D: 60 [64%] of 94), febrile neutropenia (group A: 10 [9%]; group B: 12 [11%]; group

186 common grade 3 or worse adverse events were neutropenia (group A: 71 [66%] of 107 patients; group B:

187 ethods The International Pediatric Fever and Neutropenia Guideline Panel is a multidisciplinary and m

188 ocated rolapitant versus active control were neutropenia (HEC-1: nine [3%] vs 14 [5%]; HEC-2: 16 [6%]

189 Diarrhoea, neutropenia, hypertension, and voice changes were signif

190 We studied a patient with albinism, neutropenia, immunodeficiency, neurodevelopmental delay,

191 rying clinical manifestations including mild neutropenia, impaired wound healing, severe stomatitis w

192 worse treatment-related adverse events were neutropenia in 12 (24%) patients (grade 4 in one [2%] pa

193 of 37 patients in the phase 2, and grade 3-4 neutropenia in 16 (25%) of 65 patients across phases 1 a

194 ogical; the most common of these was grade 4 neutropenia in 18 (75%) of 24 patients.

195 ombocytopenia in 48 (84%) of 57 patients and neutropenia in 45 (79%) of 57 patients.

196 telomere length on duration of post-therapy neutropenia in a pediatric AML cohort.

197 sought risk alleles for clozapine-associated neutropenia in a sample of 66 cases and 5583 clozapine-t

198 ord blood, older age, and duration of severe neutropenia in allo-HSCT, and a diagnosis of lymphoma, o

199 o determine if there is an increased risk of neutropenia in children exposed to P/T in comparison wit

200 he most common grade 3-4 adverse events were neutropenia in five patients (9%), hyponatraemia in four

201 mon grade 3 or worse adverse events included neutropenia in four patients (13%), hypertension in thre

202 respectively, are used clinically to manage neutropenia in patients undergoing chemotherapeutic trea

203 ients, thrombocytopenia in 15 (2%) patients, neutropenia in ten (1%) patients, and leucopenia in nine

204 e most frequently reported adverse event was neutropenia in ten (4%) versus 14 (5%).

205 h groups, although more patients had grade 4 neutropenia in the Bev+D-FEC group than in the D-FEC gro

206 cytopenia (in 33.8%), anemia (in 25.3%), and neutropenia (in 19.6%), which were managed with dose mod

207 (in 48%), nausea (in 47%), and grade 3 or 4 neutropenia (in 41%).

208 s of grade 3 or higher during treatment were neutropenia (in 78% of the patients), anemia (in 43%), a

209 Febrile neutropenia incidence was low (7%).

210 Three serious adverse events-febrile neutropenia, intestinal perforation, and cholangitis-wer

211 or 4 treatment-emergent adverse events were neutropenia, leukopenia, anemia, thrombocytopenia, and f

212 Prophylaxis reduced the odds of febrile neutropenia, likely bacterial infection, and bloodstream

213 These 3 patients shared congenital neutropenia linked with various other SDS phenotypes.

214 grade 4 atrial fibrillation, grade 4 febrile neutropenia, lung infection with grade 4 absolute neutro

215 ndrome is a genetic disease characterized by neutropenia, lymphopenia, susceptibility to infections,

216 t of Dengue-2 viremia that is accompanied by neutropenia, lympocytosis, hyperglycemia, and higher ret

217 Adverse events of grade 3 or higher were neutropenia (n = 2) and dizziness/vertigo (n = 1).

218 Grade 3 to 4 events were neutropenia (n = 5), nausea (n = 2), chest pain (n = 2),

219 4 nonhematologic toxicities included febrile neutropenia (n = 7) and infection (n = 4).

220 IRINOX alone were neutropenia (n=6), febrile neutropenia (n=1), anaemia (n=2), lymphopenia (n=1), dia

221 e most comment grade 3-4 adverse events were neutropenia (n=2 [5%]), hypertension (n=2 [5%]), insomni

222 the patients receiving PF-04136309 included neutropenia (n=27), febrile neutropenia (n=7), lymphopen

223 verse events in nine patients due to febrile neutropenia (n=4), diarrhoea (n=2), melena, stroke, vomi

224 of patients receiving FOLFIRINOX alone were neutropenia (n=6), febrile neutropenia (n=1), anaemia (n

225 4136309 included neutropenia (n=27), febrile neutropenia (n=7), lymphopenia (n=4), diarrhoea (n=6), a

226 ost common serious adverse event was febrile neutropenia (n=9 [11%] and n=4 [4%], respectively).

227 bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1], secon

228 Apart from neutropenia no other toxic effects were reported at grad

229 ents in the investigator's choice group) and neutropenia (none vs 14 [38%] vs four [10%]).

230 Grade 3-4 neutropenia occurred in 15 patients (33%), but only 5 (1

231 reatment in the deferred chemotherapy group, neutropenia occurred in 49 (38%) versus 36 (53%) patient

232 Grade 4 neutropenia occurred in 73.3% of patients and was transi

233 Grade 4 diarrhoea and neutropenia occurred in one patient each.

234 Anaemia, thrombocytopenia, neutropenia, oesophagitis, diarrhoea, nausea and vomitin

235 Thrombocytopenia and neutropenia of any grade were seen in the majority of co

236 Febrile neutropenia of grade 3 or higher was similar in both gro

237 tropenia (ten [3%] vs 29 [16%]), and febrile neutropenia (one [<1%] vs seven [4%]); whereas those tha

238 ile neutropenia (four [1%] vs one [<1%]) and neutropenia (one [<1%] vs two [1%]).

239 kemia cells, had severe chemotherapy-induced neutropenia or both.

240 enia, thrombocytopenia, anaemia, and febrile neutropenia or infections.

241 e of Aspergillus infections in patients with neutropenia or phagocyte functional defects, such as chr

242 V732I was associated with grade 3 or greater neutropenia (OR, 1.8 [95% CI, 1.3-2.4]).

243 ns, active use of immunosuppressive therapy, neutropenia, or bacteremia due to multidrug-resistant or

244 to follow-up, or having psychiatric illness, neutropenia, or requiring emergent care, we attempted to

245 P = .15) and were unrelated to the degree of neutropenia (P = .71) or the use of chemotherapy (P = .1

246 B, with a significant difference in grade 4 neutropenia (P = 0.002).

247 HPS2 patients present neutropenia, partial albinism, and impaired lysosomal ve

248 inaemia, and sepsis (patient number 11); and neutropenia (patient number 20).

249 ted only in severe congenital and idiopathic neutropenia patients.

250 re reported in 4 patients, including febrile neutropenia, peripheral neuropathy, and hypertension.

251 Poikiloderma with Neutropenia (PN) is an autosomal recessive genodermatosi

252 Serious adverse events, including febrile neutropenia, pneumonia, and pyrexia, were more common in

253 yonychia, hyperkeratosis, bone anomalies and neutropenia, predisposing to myelodysplasia.

254 ation, and total dose and the development of neutropenia (r = -0.121, P = .037; r = 0.267, P < .001;

255 PP was associated with reduced risk of neutropenia-related hospitalization for TC (2.0% PP; 7.1

256 iated with low-to-modest benefit in lowering neutropenia-related hospitalization in patients with bre

257 ith low-to-intermediate risk of induction of neutropenia-related hospitalization.

258 have to be treated for 21 days to avoid one neutropenia-related hospitalization; with the TCH regime

259 in apoptotic processes in severe congenital neutropenia (SCN) 3 (Kostmann disease [caused by HAX1 mu

260 Severe congenital neutropenia (SCN) and Shwachman-Diamond syndrome (SDS) a

261 majority of patients with severe congenital neutropenia (SCN).

262 ount decreased (five [8%] vs four [6%]), and neutropenia (six [10%] vs one [2%]).

263 eight [16%]), anaemia (seven [14%]), febrile neutropenia (six [12%]), and leucopenia (six [12%]).

264 m three unrelated pedigrees characterized by neutropenia, specific granule deficiency, myelodysplasia

265 achman-Diamond syndrome (SDS) are congenital neutropenia syndromes with a high rate of leukemic trans

266 the treatment of physician's choice group), neutropenia (ten [3%] vs 29 [16%]), and febrile neutrope

267 ue or asthenia (eight [4%] vs two [2%]), and neutropenia (ten [5%] vs four [4%]).

268 ons and higher rates of thrombocytopenia and neutropenia than bortezomib and dexamethasone alone.

269 rinary excretion of 3-methylglutaconic acid, neutropenia that can develop into leukemia, a neurologic

270 Healthy individuals of African ancestry have neutropenia that has been linked with the variant rs2814

271 Aside from increased neutropenia, the safety profile of daratumumab plus pom-

272 penia (four [4%]), anaemia (three [3%]), and neutropenia (three [3%]) in the taxane group.

273 mbocytopenia (in nine [20%] of 44 patients), neutropenia (three [7%]), and hyperglycaemia (three [7%]

274 3-4 adverse events in all three groups were neutropenia, thrombocytopenia, anaemia, and febrile neut

275 Grade 3 to 4 adverse events (>/=5%) included neutropenia, thrombocytopenia, and anemia.

276 Grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia occurred

277 l of 46 genes on 80 patients with congenital neutropenia to assess for clonal hematopoiesis.

278 ies derived from 13 patients with congenital neutropenia to measure total mutation burden and perform

279 g factor (GCSF) is a well-known cytokine for neutropenia treatment.

280 [2%]), anaemia (five [2%] vs six [5%]), and neutropenia (two [1%] vs ten [9%]).

281 5%] of 37), haemolysis (two [5%] of 37), and neutropenia (two [5%] of 37).

282 and diarrhea (13%); the incidence of febrile neutropenia was 7%.

283 groups (8.1% vs 8.3%, p=0.93), but grade 3-4 neutropenia was more frequent in the co-trimoxazole grou

284 Grade 3-4 neutropenia was reported in 45 (54%) of 83 patients in t

285 Because neutropenia was seldom observed in children treated with

286 The rate of grade 3 or 4 neutropenia was significantly higher in the transplantat

287 expected chemotherapy toxicity was seen, and neutropenia was the most commonly reported event (grade

288 Neutropenia was the most frequent grade >/= 3 adverse ev

289 oxicities, grade 3 to 4 thrombocytopenia and neutropenia were each experienced by eight patients (13.

290 Rates of neutropenia were higher with brodalumab and with ustekin

291 nib 43.2% v placebo 12.2%); rates of febrile neutropenia were low (4.5% in nintedanib group v 0% in p

292 Thirteen cases of neutropenia were observed during the study period.

293 -linked thrombocytopenia (XLT), and X-linked neutropenia, which are caused by WAS mutations affecting

294 t common grade 3 or higher adverse event was neutropenia, which occurred in 44 patients (21%) in the

295 te CSF (G-CSF), a common treatment of severe neutropenia, which showed no protective effect under the

296 e patient had developed thrombocytopenia and neutropenia, which was initially thought to be drug indu

297 ed in 20 participants (including 40% who had neutropenia) who were colonized by a median of 2 (range,

298 protein-targeting pathway, lead to syndromic neutropenia with a Shwachman-Diamond-like phenotype.

299 except there was significantly more grade 4 neutropenia with twice-daily radiotherapy (129 [49%] vs

300 % in MAP vs 248 [83%] in MAPIE), and febrile neutropenia without documented infection (149 [50%] in M